Roche Roferon-A chronic myelogenous leukemia indication clears FDA Oct. 19.
Executive Summary
ROCHE ROFERON-A CHRONIC MYELOGENOUS LEUKEMIA INDICATION APPROVED by FDA Oct. 19. New labeling states that Roferon-A "is indicated for chronic phase, Philadelphia chromosome (Ph) positive CML patients who are minimally pretreated (within one year of diagnosis)." The drug also is indicated for treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma in adult patients.